Telix Pharmaceuticals gets FDA approval for Illuccix label expansion, stock has potential growth

From Yahoo Finance: 2025-06-29 13:28:00

Telix Pharmaceuticals Limited (NASDAQ: TLX) receives US FDA approval for label expansion of Illuccix® to include patient selection for radioligand therapy in the pre-taxane setting. The expansion is expected to increase clinical utilization by at least 20,000 scans annually. Q1 2025 unaudited revenue for Telix Pharmaceuticals Limited was approximately $186 million, a 62% increase from the prior year. The company’s stock has a consensus one-year price target of $22.90. Despite potential growth, some believe other AI stocks offer greater promise for higher returns with limited downside risk.



Read more at Yahoo Finance: Telix Pharmaceuticals (TLX) Announces That US FDA Approves Label Expansion for Illuccix